Latest Cypher-Taxus Battle a Wash

The American College of Cardiology meeting is an event where the latest cardiovascular studies are presented, sometimes revealing a bombshell. But that didn't happen this year, at least in the ongoing battle between Johnson & Johnson's Cypher and Boston Scientific Corp.'s Taxus for the lucrative drug-eluting stent market. Bloomberg News reports that the research presented at ACC over the weekend doesn't give an advantage to either product. Both were found about equally superior to radiation therapy, and both were found to be similarly effective in diabetics. Expect more head-to-head studies in the future as each firm looks for whatever competitive advantage it can get.
Device talk Tags: